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Conventional measures such as maximum plasma concentration (Cmax) and area under the concentration versus
time curve (AUC) may be insufficient to fully describe the pharmacokinetic (PK) profile of extended-release (ER)
formulations. A complementary measure, the half-value duration (HVD), corresponds to the period of time during a
dosing cycle that plasma concentration is at or above half the value of the maximal concentration (i.e. ≥50% Cmax).
The current post-hoc analysis uses data from 2 previously published studies comparing the PK profiles and HVD of OROS
hydromorphone ER (16 mg administered once daily) and immediate-release (IR) hydromorphone (4 mg administered
every 6 hours), calculating single-dose and steady-state condition values. Bioequivalence was demonstrated between
the 2 formulations. Mean steady-state once-daily OROS hydromorphone ER concentrations were elevated for most of
the 24-hour dosing period and for significantly longer than with the dose-equivalent IR hydromorphone regimen. The
duration of time spent ≥50% Cmax was, on average, 2.7 times longer at steady state for the ER formulation, which also
maintained steady-state hydromorphone plasma concentrations, with 65% lower mean degree of fluctuation versus IR
hydromorphone. Both formulations appeared to be well tolerated.
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Hydromorphone, an opioid analgesic introduced into
clinical practice in the 1920s, has been used extensively to
treat pain (Quigley and Wiffen 2003). The pharmacokinetic
(PK) profile of OROS hydromorphone extended-release
(ER) is well established in healthy subjects, with controlled
release resulting in sustained plasma concentrations (Angst
et al. 2001; Drover et al. 2002; Moore et al. 2010; Moore
et al. 2011; Sathyan et al. 2007; Sathyan et al. 2008). The
hydromorphone release rate is independent of pH and
gastric motility (Gupta and Sathyan 2007), and relatively
unaffected by alcohol, rendering “dose dumping” unlikely
(Sathyan et al. 2008). OROS hydromorphone ER reaches
maximum plasma concentration (Cmax) 12 to 16 hours after
administration and produces sustained hydromorphone* Correspondence: krishna.devarakonda@mallinckrodt.com
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reproduction in any medium, provided the origconcentrations over 24 hours, with dose-proportional
PK (Drover et al. 2002; Sathyan et al. 2007; Gupta and
Sathyan 2007). OROS hydromorphone ER has a long
half-life (~13 to 15 hours) and requires 3 to 4 days to
reach steady-state plasma hydromorphone concentrations
(Moore et al. 2010; Moore et al. 2011; Sathyan et al. 2007;
Gupta and Sathyan 2007).
Though PK measures such as Cmax and area under the
concentration versus time curve (AUC) describe properties
of conventional opioid formulations, they may be insuffi-
cient or misleading for modified-release formulations.
PK parameters must quantify the constant rate of controlled
release in opioids and facilitate comparisons between
formulations with respect to rate and extent of absorption
(i.e. bioavailability/bioequivalence) (Steinijans 1990). The
degree of peak-to-trough fluctuation is one metric for
evaluating modified-release dosing regimens, including
ER opioids. These fluctuations are lessened with OROShis is an open access article distributed under the terms of the Creative
mmons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
inal work is properly cited.
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ate-release (IR) hydromorphone (172%) (Moore et al. 2010).
A complementary measure of modified-release drug
performance, “plateau time”—the period of time during
a dosing cycle over which plasma concentration deviates
from the maximum by less than a specified percentage
(Steinijans 1990)—has been applied to calibrate the per-
formance of multiple ER formulations (Steinijans 1990;
Bialer et al. 1998; Drewe et al. 1992). Various percentage
thresholds have been proposed as clinically relevant
correlates of the width of the efficacy range for ER drugs,
including the duration of plasma concentrations at
or above half the value of the maximal concentration
(i.e. ≥50% Cmax, also referred to as “half-value duration”
[HVD]) (Steinijans 1990; Bialer et al. 1998; Drewe et al.
1992; Meier et al. 1974; Guttler 2012). Other thresholds
(e.g. ≥75% or ≥80%) have also been used (Steinijans 1990;
Meier et al. 1974). In an experimental pain model using
OROS hydromorphone ER, hydromorphone concentration
peaked significantly later (median, 12 vs. 0.8 hours) and
remained ≥50% Cmax substantially longer (mean, 22.7
hours) than concentrations following a single dose of IR
hydromorphone (1.1 hours). Analgesic effects also peaked
significantly later (9.0 vs. 1.5 hours) and were maintained
significantly longer at >50% peak analgesic effect (13.3
vs. 3.6 hours). There was a significant linear relationship
(P < 0.05) between hydromorphone plasma concentration
and analgesia (Angst et al. 2001).
The current analysis used data from 2 previously
published studies in healthy subjects: one assessing effects
of food on the PK of single doses of the OROS formulation
compared with 4 doses of IR hydromorphone (Study A)
(Moore et al. 2011), and one characterizing the steady-state
PK of OROS and IR hydromorphone (Study B) (Moore
et al. 2010). We sought to further characterize the single-
dose and steady-state PK profiles of hydromorphone by
evaluating time ≥50% Cmax in healthy subjects after
administration of oral OROS hydromorphone ER.
The current analysis was presented separately for both
Study A (Richarz et al. 2011a) and Study B (Richarz et al.
2011b) in poster form at the American Pain Society
30th Annual Scientific Meeting, May 18–21, 2011, in
Austin, TX.
Methods
Detailed methods for each study have been published
elsewhere (Moore et al. 2010; Moore et al. 2011).
Participants
Study A (single dose, fed, or fasted) and Study B (steady
state) were conducted according to the principles of
the Declaration of Helsinki and current International
Conference on Harmonization guidelines on Good Clin-
ical Practice. Both study protocols were approved by anInstitutional Review Board convening at MDS Pharma
Services, Montréal, Québec, Canada. All subjects provided
written informed consent.
Both studies enrolled men and women aged 18 to 55
years who were considered healthy, with a body mass index
of 18 kg/m2 to 30 kg/m2 and body weight ≥50 kg. Subjects
with a history of illness or current medical illness were
excluded. Medication use (other than hormone replacement
therapy, oral contraceptives, or acetaminophen) within
14 days prior to study treatment was prohibited. Subjects
with a history or believed history of drug or alcohol abuse
within the past 5 years were also excluded; a naloxone
0.8-mg injection was administered prior to study random-
ization and medication dosing to detect opioid dependence
(Moore et al. 2010; Moore et al. 2011).
Study design
Study A
Study A was a randomized, open-label, single-center,
3-period, crossover study. Following screening, subjects
entered an open-label treatment phase consisting of 3
treatment periods, each 5 days in duration. All subjects
received each of 3 treatments: a single oral dose of OROS
hydromorphone ER 16 mg under fasting conditions (Treat-
ment A); 4 oral doses of IR hydromorphone 4 mg every 6
hours over 24 hours under fasting conditions (Treatment
B); and a single oral dose of OROS hydromorphone ER 16
mg under fed conditions (Treatment C, given immediately
following the completion of a high-fat meal). Subjects were
randomly assigned by a computer-generated schedule
to receive each of the 3 treatments in 1 of 6 possible se-
quences (Additional file 1: Figure S1a) (Moore et al. 2011).
Each treatment period was separated by a washout period
of ≥7 and ≤14 days after dosing; given the approximate
13- to 15-hour apparent elimination half-life (t1/2,λ) of
OROS hydromorphone ER, a maximum washout period
of 2 weeks was thought to be sufficient to avoid any carry-
over effect that might influence analyses (Moore et al.
2011; Gupta and Sathyan 2007).
Subjects treated under fasting conditions fasted for ≥12
hours before dosing, whereas subjects treated under a fed
state received dosing immediately following the completion
of a high-fat meal. During each period, all subjects received
a concomitant dosing regimen of naltrexone 50-mg oral
tablets to counter the opioid effects of hydromorphone
(7 single doses, 14 and 2 hours before the study drug dose
and every 12 hours thereafter, up to 58 hours post-study
drug dose) (Moore et al. 2011).
Study B
Study B was a randomized, open-label, single-center,
multidose, 2-period, crossover study (Additional file 1:
Figure S1b) (Moore et al. 2010). Subjects were randomly
assigned to one of 2 possible treatment sequence groups
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OROS hydromorphone ER administered orally once
daily for 5 days and 4 mg IR hydromorphone administered
orally every 6 hours for 5 days. Treatment periods were
separated by a washout period of between 7 and 14 days
after dosing. To block the subjective effects of hydromor-
phone, naltrexone 50 mg was given 14 and 2 hours before
the first dose, and every 12 hours until 130 hours after
initial dosing (Moore et al. 2010).Table 1 Mean (SD) pharmacokinetic parameters after
single dosing and at steady state for OROS
hydromorphone ER and IR hydromorphone in healthy
subjectsPharmacokinetic sampling and analysis
Study A
The PK sampling is explained in detail elsewhere (Moore
et al. 2011). Briefly, venous blood samples for measurement
of plasma hydromorphone concentrations were collected
before dosing and at regular intervals after dosing until
72 hours post-dose. Concentrations of hydromorphone
in plasma were measured by high-performance liquid
chromatography (HPLC)–tandem mass spectrometry.
The following PK parameters were estimated from the
plasma data: AUC from time 0 to time of the last quantifi-
able concentration (AUClast); AUC from time 0 to over 24
hours (AUC0-24); the AUC extrapolated to infinity (AUC∞);
Cmax; time to Cmax (tmax); t1/2,λ; and the first-order elimin-





No. of subjects 29 30 30
AUClast, ng•h/mL 45.9 (11.2) 46.9 (13.8) 43.9 (10.4)
AUC0-24, ng•h/mL 25.6 (6.5) 25.7 (6.6) 30 (7.6)
Cmax, ng/mL 1.8 (0.5) 1.9 (0.5) 3.6 (1.5)
tmax, h
a 16 (5.9–24.2) 17.9 (6.0–24.2) 18.5 (18.5–20.0)
t½,λ, h 14.4 (4.1) 14.4 (6.0) 12.7 (3.4)
Time ≥50% Cmax, h 23.6 (8.0) 21.6 (6.7) 5.9 (4.1)
Study B
No. of subjects 29 30
AUC0-24, ng•h/mL 57.6 (16.3) 54.8 (14.8)
Cmaxss, ng/mL 3.54 (0.96) 5.28 (1.37)
Cminss, ng/mL 2.15 (0.87) 1.47 (0.42)
tmaxss, h
a 11.9 (5.9–24.2) 7.0 (0.5–18.8)
Peak-to-trough 60.5 (41.1) 172 (57.6)Study B
Venous blood samples for measurement of plasma hydro-
morphone concentrations were collected before dosing and
at regular intervals after dosing until 120 hours postdose;
further sampling between 96 and 120 hours was under-
taken to characterize the steady-state profile of each
formulation. Similar to Study A, hydromorphone plasma
concentrations were measured by means of a validated and
specific HPLC–tandem mass spectrometry technique, with
a range of 0.05 ng/mL to 10.0 ng/mL. Primary PK analyses
included AUC0-24; maximum plasma concentration at steady
state (Cmaxss); time to Cmaxss (tmaxss); trough plasma con-
centration at steady state (Cminss); and degree of fluctuation.
Percentage fluctuations in hydromorphone concentrations
(flux) were calculated from the formula ((Cmaxss – Cminss)/
Cssav) × 100, where Cssav is calculated as the ratio of AUC0-24
to the dosing interval τ (24 hours) (Moore et al. 2010).fluctuation (flux), %
Time ≥50% Cmax, h 20.5 (4.1) 7.5 (4.8)
AUC0-24, area under the concentration versus time curve from time 0 to 24
hours postdose; AUClast, area under the concentration versus time curve from
time 0 to the last quantifiable concentration; Cmax, maximum plasma
concentration; Cmaxss, maximum plasma concentration at steady state; Cminss,
trough plasma concentration at steady state; ER, extended-release; IR,
immediate-release; t½,λ, apparent elimination half-life; tmax, time to maximum
plasma concentration; tmaxss, time to maximum plasma concentration at
steady state.
a. Median (range) reported for tmax.Safety evaluation
Safety in each study was evaluated by monitoring adverse
events (AEs), physical examination, vital signs, clinical
laboratory tests, and electrocardiographic monitoring.
Continuous pulse oximetry was undertaken and respiration
rate was monitored while patients were sleeping (Moore
et al. 2010; Moore et al. 2011).Statistical analyses
For the present analyses, individual and mean plasma
concentration-versus-time profiles were generated within
each study. For each treatment, descriptive statistics were
calculated for all PK parameters of hydromorphone.
A steady-state analysis using a mixed-effects analysis of
variance (ANOVA) model with Helmert contrasts was
performed to identify attainment of steady state in plasma
hydromorphone concentrations. The model included treat-
ment-sequence group, period, treatment, and time as
fixed effects. Steady-state conditions were assumed if the
Helmert contrasts were not significantly different on at
least 3 predose values, assuming an α-level of 0.05. The
total time spent at ≥50% Cmax was calculated for both
studies, using linear interpolation between the plasma
concentration time points that crossed the 50% Cmax
threshold. Time above 50% of Cmax was analyzed using a
mixed-effects model with sequence, period, and treatment
as fixed effects and subject-within-sequence as a random
effect to account for the crossover design. The difference
in least-square means between OROS hydromorphone ER
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significant if P < 0.05.
The analyses included only data from participants who
completed all PK assessments and was performed using
the SAS® (SAS Institute, Cary, NC, USA) MIXED and
GLM procedures (Moore et al. 2010; Moore et al. 2011).
Results
Subject disposition and demographics
Thirty subjects were enrolled into each study. Fifty-nine
subjects completed all treatment periods and were in-
cluded in the PK analyses. One subject was withdrawn
from Study B prior to dosing due to elevated creatine
phosphokinase levels. The mean age of subjects in Study A
was 42 ± 9 years, and 77% were male; mean age in Study B
was 39 ± 8.5 years, and 50% were male. Full demographicFigure 1 Plasma hydromorphone concentration profiles for OROS hyd
concentration profiles after single dosing (a) and at steady state (b). ER, excharacteristics of the subjects have been presented previ-
ously (Moore et al. 2010; Moore et al. 2011).Pharmacokinetic analysis
Concentration-time profiles
In Study A, mean AUC comparisons of 16 mg OROS
hydromorphone ER and IR hydromorphone 4 mg every 6
hours indicated bioequivalence in the fasted state (Table 1)
(Moore et al. 2011). Mean Cmax of IR hydromorphone
in the initial 24-hour interval under fasted conditions was
89% and 100% higher than OROS hydromorphone ER
under fasted and fed conditions, respectively (Table 1,
Figure 1a) (Moore et al. 2011). Individual PK parameters
for OROS hydromorphone ER were comparable under fed
and fasted conditions (Table 1) (Moore et al. 2011).romorphone ER and IR hydromorphone. Panels show
tended-release; IR, immediate-release.
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cessfully maintained steady-state hydromorphone plasma
concentrations within the same concentration range as
4 mg IR hydromorphone every 6 hours (administered at
the same total daily dose) (Table 1) (Moore et al. 2010).
Overall exposure to hydromorphone was similar with both
treatments, as measured using AUC0-24 (Table 1) (Moore
et al. 2010). The observed median tmaxss of OROS hydro-
morphone ER (11.9 hours) occurred approximately 5 hours
after the tmaxss for IR hydromorphone (7.0 hours) (Table 1)
(Moore et al. 2010).
At steady state, the mean (SD) degree of peak-to-trough
fluctuation (flux) was 60.5% (41.1%) for OROS hydromor-
phone ER, compared with 172% (57.6%) with IR hydro-
morphone (Table 1) (Moore et al. 2010). Mean plasma
hydromorphone concentrations over time for OROSFigure 2 Percentage of subjects with plasma hydromorphone concen
hydromorphone ER and IR hydromorphone. Panels show percentages a
concentration; ER, extended-release; IR, immediate-release.hydromorphone ER and IR hydromorphone at steady state
(day 5) are presented in Figure 1b (Moore et al. 2010).
Half-value duration (HVD)
Compared with IR hydromorphone, a greater percentage
of subjects receiving OROS hydromorphone ER had
hydromorphone plasma concentrations ≥50% Cmax at
each time point after dosing in Study A (Figure 2a) and
at all time points from 2 hours after dosing in Study B
(Figure 2b). Based on individual subject data, a single
16-mg dose of OROS hydromorphone ER sustained plasma
concentrations ≥50% Cmax for a mean (SD) of 23.6 (8.0)
hours and 21.6 (6.7) hours under fed and fasted conditions,
respectively, compared with 5.9 (4.1) hours after a 16-mg
total daily dose (given as 4 × 4-mg doses) of IR hydromor-
phone (P < 0.0001 for each OROS vs. IR comparison; Table 1trations ≥50% Cmax at each time point after dosing with OROS
fter single dosing (a) and at steady state (b). Cmax, maximum plasma
Devarakonda et al. SpringerPlus 2013, 2:625 Page 6 of 9
http://www.springerplus.com/content/2/1/625and Figure 3a) (Moore et al. 2010; Moore et al. 2011).
Plasma hydromorphone concentrations remained ≥50%
Cmax ≥20 hours in approximately 70.0% of subjects after a
single 16-mg dose of OROS hydromorphone ER. This
occurred in no subjects who received a 16-mg total daily
dose of IR hydromorphone (Figure 4a). At steady state,
the mean (SD) time spent ≥50% Cmax was 20.5 (4.1) hours
for OROS hydromorphone ER and 7.5 (4.8) hours for
IR hydromorphone (Table 1 and Figure 3b) (Moore
et al. 2010; Moore et al. 2011). The time spent ≥50%
Cmax at steady state ranged from 9.1 to 24.0 hours
(where it was capped) for the OROS hydromorphone ER
and from 1.0 to 18.2 hours for IR hydromorphone (4 doses
per day). Steady-state hydromorphone plasma concentra-
tions remained at ≥50% Cmax for ≥20 hours in 58.6% of
subjects receiving OROS hydromorphone ER, comparedFigure 3 Mean time spent ≥50% Cmax for OROS hydromorphone ER
after single doses of OROS hydromorphone ER and 4 doses of IR hydromo
concentration; ER, extended-release; IR, immediate-release.with no subjects receiving IR hydromorphone at the same
total daily dose (Figure 4b). Steady-state plasma concen-
trations remained ≥50% Cmax for ≥16 hours in 89.7%
and 6.9% of subjects, respectively (Figure 4b) (Moore et al.
2010; Moore et al. 2011).
Safety
Study A
A total of 46 mild to moderate AEs were reported by 17
subjects (56.7%). Seventeen (37%) AEs were reported
with OROS hydromorphone ER fasted, 21 (46%) AEs
were reported with OROS hydromorphone ER fed,
and 8 (17%) AEs were reported with IR hydromorphone
fasted. Overall, the highest incidences of AEs were
headache, dizziness, and constipation (Table 2) (Moore
et al. 2011).and IR hydromorphone. Panels show mean time spent ≥50% Cmax
rphone (a), and at steady state (b). Cmax, maximum plasma
Figure 4 Time spent ≥50% Cmax for OROS hydromorphone ER and IR hydromorphone by subject. Panels show time spent ≥50% Cmax
by subject after single dosing (a), and at steady state (b). Cmax, maximum plasma concentration; ER, extended-release; IR, immediate-release.
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Overall, 21 AEs were reported by 7 subjects (24%) receiving
OROS hydromorphone ER and 16 AEs were reported by
10 subjects (34.5%) receiving IR hydromorphone. The most
commonly reported treatment-emergent AEs occurring in
≥5% of subjects are presented in Table 2 (Moore et al.
2010). Chest pain occurred in 2 patients during the OROS
and IR administration and each event was considered mild
and unlikely to be related to study medication. Localized
erythema occurred in 2 subjects during OROS adminis-
tration and 1 subject during IR administration. All events
were considered mild in severity; erythema was considered
possibly related to study medication in only 1 subject
(during OROS administration) (Moore et al. 2010).
Both OROS hydromorphone ER and IR hydromorphone,
administered in conjunction with naltrexone to counter theopioid effects of hydromorphone, appeared to be generally
safe and well tolerated, with no serious AEs occurring
during either study (Moore et al. 2010; Moore et al. 2011).
Discussion and conclusions
The current analysis demonstrated bioequivalence of once-
daily OROS hydromorphone ER and 4-times-daily IR
hydromorphone at equivalent total daily doses. HVD,
which corresponds to the length of time that plasma
concentrations are ≥50% Cmax, has been applied comple-
mentarily to conventional parameters as a measure of the
performance of ER formulations (Steinijans 1990; Drewe
et al. 1992; Meier et al. 1974). Despite the higher Cmax
with each 4-mg dose of IR hydromorphone compared with
the OROS formulation, the time spent at ≥50% Cmax
for subjects receiving OROS hydromorphone ER was, on
Table 2 Incidence of treatment-emergent adverse events
occurring in ≥1 patient overall in each study
Adverse event,
n (%)
OROS hydromorphone ER IR hydromorphone,
fasted (n = 30)Fed (n = 29) Fasted (n = 30)
Study A
Headache 2 (7) 3 (10) 1 (3)
Dizziness 1 (3) 1 (3) 1 (3)
Constipation 1 (3) 1 (3) 1 (3)
Abdominal
pain, upper
1 (3) 1 (3) 0 (0)
Nausea 2 (7) 0 (0) 0 (0)
Vomiting 1 (3) 1 (3) 0 (0)
Hyperhidrosis 1 (3) 1 (3) 0 (0)
Study B OROS hydromorphone
ER (n = 29)
IR hydromorphone
(n = 30)
Chest pain 2 (6.9) 2 (6.7)
Erythema 2 (6.9) 1 (3.3)
Pruritus 2 (6.9) 1 (3.3)
Constipation 1 (3.4) 1 (3.3)
Fatigue 1 (3.4) 1 (3.3)
Headache 1 (3.4) 1 (3.3)
Somnolence 1 (3.4) 1 (3.3)
ER, extended-release; IR, immediate-release.
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receiving 4 doses of IR hydromorphone over a 24-hour
period. These data are consistent with results reported by
Angst et al. (2001), in which the mean (SD) duration of
hydromorphone plasma concentration ≥50% Cmax was
21.6 (8.1) hours in subjects following a single dose of 16
mg OROS hydromorphone ER (Angst et al. 2001).
In the current analysis, once-daily OROS hydromorphone
ER tablets were shown to successfully maintain steady-state
hydromorphone plasma concentrations by day 4 within
the same concentration range as the 4-times-daily IR
hydromorphone tablets (administered at the same total
dose per day) but with less fluctuation. The mean degree
of fluctuation for OROS hydromorphone ER was 65%
lower than that observed with IR hydromorphone (Moore
et al. 2010). These data also demonstrate that mean
steady-state once-daily OROS hydromorphone ER con-
centrations are elevated for most of the 24-hour dosing
period and for significantly longer than with the IR
hydromorphone dosing regimen at the same total daily
dose, due to the gradual release of hydromorphone from
the tablet and ongoing enterohepatic circulation of the
drug over the dosing period.
Although OROS hydromorphone ER and IR hydromor-
phone had comparable AUC data, the ER formulation—
with its extended period of time during which plasma
concentrations are ≥50% Cmax—may be beneficial inpatients with chronic pain who require around-the-clock
opioid therapy. Although the parameters presented do
not necessarily imply analgesia per se, they do support a
consistent performance for this formulation over time.
When administered for up to 5 consecutive days, both
OROS hydromorphone ER and IR hydromorphone ap-
peared to be well tolerated in healthy subjects. It should
be noted that, as is common in PK studies of this nature,
naltrexone was administered to reduce the likelihood of
opioid-related AEs. Naltrexone could potentially alter
the PK profile of hydromorphone, because it reverses the
slowing of gastric transit associated with opioids (Murphy
et al. 1997). This is a potential limitation of this study,
although it should be acknowledged that all treatment
groups received naltrexone. Earlier work showed that,
although coadministration of OROS hydromorphone with
naltrexone under fasting conditions resulted in a 39%
increase in Cmax, this was not accompanied by significant
changes in tmax; AUC from time zero to τ (AUC0-τ), where τ
is the last 24-hour dosing interval; or AUC∞ (Sathyan
et al. 2007). The PK results from the current studies are
consistent with those reported by Angst et al. (2001), in
which naltrexone was not used in conjunction with hydro-
morphone (Angst et al. 2001).
The post-hoc nature of the analysis is another limitation
of the study. These studies were not specifically designed
to correlate PK measures with analgesia; therefore, no
conclusions about HVD as a predictor of duration of
efficacy can be drawn. However, the HVD (and flux) offer
information about the stability of plasma concentrations
over time with ER analgesics, which may be important in
populations receiving multiple doses of analgesics over a
prolonged period of time.
Additional studies will be necessary to fully evaluate the
relationship of the time spent ≥50% Cmax to duration of
analgesic effect associated with OROS hydromorphone ER.
Additional prospective studies in chronic pain sufferers
may help verify the extent to which HVD or other plateau
times can differentiate the profile of ER versus IR opioids,
and the degree to which such differences are associated
with sustained analgesia and other functional improvements.
Ethical standards statement
The 2 studies reported on in this paper conformed to the
laws of the United States and Canada.
Additional file
Additional file 1: Figure S1. Study periods and treatments. Participants
in Study A were randomly assigned to one of 6 possible treatment
sequences. Treatment A consisted of single doses of OROS hydromorphone
ER 16 mg administered under fasted conditions; Treatment B consisted of IR
hydromorphone 16 mg (4 mg every 6 hours for 24 hours) under fasted
conditions; Treatment C consisted of single doses of OROS hydromorphone
ER 16 mg immediately following the completion of a standard high-fat
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(total daily dose) for 5 sequential days each in one of two sequences (b).
ER, extended-release; IR, immediate-release.
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